Back to search
Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Mucosa Associated Lymphoid Tissue (MALT) Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Mucosa Associated Lymphoid Tissue (MALT) Lymphoma trials you may qualify forThis phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphom…
This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells call…
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Zanubrutinib in combination with Rituximab as a f…
The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in…
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors pre…
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies. Giving chemotherapy…
This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphom…
This phase I trial studies the side effects and best dose of BTK inhibitor PCI-32765 when given together with rituximab and bendamustine hydrochloride in treati…